Boston Scientific stock dipped Wednesday, but the medtech company beat Wall Street's fourth-quarter forecasts.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...

A study of Boston Scientific’s Farapulse pulsed field ablation system met safety and efficacy objectives in people with persistent atrial fibrillation (AFib), an irregular heart rhythm that lasts more ...

Interventional Cardiology Therapies, Boston Scientific "Bolt Medical is developing a next-generation technology that is highly complementary to our existing portfolio. The addition of this system ...

"The increasing prevalence of cardiovascular conditions in younger people has many factors. Key contributors include obesity, sedentary behavior, and diets rich in ultra-processed foods," she explains ...